PMID: 8611481Apr 1, 1996Paper

Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above

British Journal of Haematology
M DeLimaElihu Estey

Abstract

In order to assess outcome following treatment of acute myeloid leukaemia (AML) in patients aged 80 years and above, we have studied 33 patients aged > or = 80 years treated between 1980 and 1994; 29 of these received treatment. The median age was 82 years (range 80-89). Three patients received daunorubicin ( > or = 60 mg/m2 daily x 3) alone or with low-dose ara-C, two patients received '3+7' with post treatment GM-CSF; 24 patients had higher doses of ara-C, generally with anthracyclines or fludarabine, and in nine cases with G or GM-CSF. The median survival of the treated patients was 3-4 weeks and only two were alive after 1 year (at 66 and 79 weeks). Complete remission (CR) occurred in 9/29 (31%). Only one of the nine remains alive in remission, at 76 weeks after the date of CR, whereas the other eight died in remission or had disease recurrence at a median of 11 weeks (range 5-37 weeks) after CR. The median survival of the four untreated patients was 10 weeks (range 3-38). Patients aged > or = 80 had, on average, worse outcomes than those observed in patients aged 70-79. Our results confirm that currently available chemotherapy is generally not indicated in patients aged 80 or over with AML.

Citations

Jul 10, 1999·Leukemia Research·R LatagliataF Mandelli
Aug 14, 2001·Critical Reviews in Oncology/hematology·A PintoF Ferrara
Dec 6, 2005·Leukemia·G JuliussonUNKNOWN Swedish Adult Acute Leukemia Registry Group
Sep 4, 2003·Leukemia & Lymphoma·Annalaura Di FeboLivio Pagano
Mar 23, 2011·Expert Opinion on Emerging Drugs·Hillary PrescottFarhad Ravandi
Apr 20, 2011·Expert Opinion on Drug Metabolism & Toxicology·Jeffrey BryanElias Jabbour
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Laurie D DeLeveUNKNOWN American Association for the Study Liver Diseases
Feb 10, 2011·Geriatrics & Gerontology International·Shine AbeToshihiko Iwamoto
Jan 1, 1997·Current Problems in Cancer·L D Cripe
Mar 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Betul OranMarcos de Lima
Jul 9, 2004·Cancer·Norbert VeyDominique Maraninchi
Nov 26, 2002·American Journal of Hematology·Roberto LatagliataFranco Mandelli
Nov 26, 2010·Expert Review of Hematology·Karen W L Yee, Armand Keating
Feb 7, 2013·Current Opinion in Hematology·Timothy Kubal, Jeffrey E Lancet
Aug 18, 2017·Expert Review of Hematology·Claudia BrunettiFrancesco Albano
Jun 16, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C-C ChenJ-P Gau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.